secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001493152-22-016325
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics amends license with UCLA, deferring $8M diligence fee tied to future sales milestones
--------------------------------------------------------------------------------

- Third Amendment extends development milestones; UCLA defers $8M diligence fee until first sale of licensed product.
- $8M fee payable in tranches: $2M at $50M net sales, $2M at $100M, $4M at $200M cumulative net sales.
- Obligation survives termination; assets cannot be transferred without assigning fee or paying within 10 days.
- New milestones include initiating Phase I/II pilot study by Dec 31, 2024, and pegylated product milestones through 2030s.
- Company must spend at least $1M per year on pre-clinical/clinical development until Phase III completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315222016325/0001493152-22-016325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315222016325/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-016325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer